Abbott Laboratories stock faces test as Nutrition separation advances

Abbott Laboratories is moving ahead with plans announced on October 21, 2026, to separate its global Nutrition business into an independent publicly traded company. The transaction gives investors a new portfolio milestone to track as Abbott focuses on medical devices, diagnostics and established medicines.

Abbott's MediaRoom release said the new company is expected to generate approximately 8.5 billion US dollars in annual sales, employ about 16,000 people and operate 14 manufacturing sites. Its brands are expected to include Similac, PediaSure, Pedialyte, Glucerna and Ensure.

Execution remains the central issue

Abbott intends to distribute shares in the new company to existing shareholders, who would own shares in both businesses after completion. The Nutrition operation will continue within Abbott during the separation process, with Daniel Salvadori expected to become chief executive of the new company.

Completion is targeted for the end of 2027, subject to regulatory approvals, the effectiveness of a Form 10 registration statement and final approval by Abbott's board. Abbott has said the plan will not affect its 2026 guidance or the 2027 guidance it plans to provide in January, although one-time transaction charges are expected before completion.

Stock trades below prior Xetra close

Abbott Laboratories stock traded at 99.44 euros on Lang & Schwarz at 15:32 CET on Friday, November 6, 2026, 1.69 percent below the Xetra close of Thursday, November 5, at 101.15 euros. The quote is 4.46 percent below the 104.08 euros recorded at 16:04 CET on November 5 in the previous report, a separate comparison from the Xetra session move. Investors can follow the real-time quote of Abbott Laboratories stock.

US healthcare sentiment can be followed through the S&P 500.

More news and analyses on Abbott Laboratories stock will track regulatory filings, the separation timetable and Abbott's 2027 guidance.